Bayer, Orion prostate cancer drug cuts risk of metastasis or death by more than 50% in key study
As Merck and Bristol-Myers look toward prostate cancer as the next battleground for immuno-oncology dominance, Bayer and partner Orion broke out the numbers that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
